Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1996 Apr;87(4):395-400.
doi: 10.1111/j.1349-7006.1996.tb00235.x.

Characterization of transendothelial migratory lymphokine-activated killer cells

K Nakano  1 , M Eura, K Chikamatsu, K Masuyama, T Ishikawa
Affiliations

Characterization of transendothelial migratory lymphokine-activated killer cells

K Nakano et al. Jpn J Cancer Res. 1996 Apr.

Abstract

We examined the killing activity of transmigrated lymphokine-activated killer (LAK) cells and their surface molecules associated with both transendothelial migration and cytotoxicity, using human umbilical vein-derived endothelial cell (HUVEC) monolayers on fibronectin with gelatin separating the upper chamber from the lower chamber. Migratory LAK cells were significantly more cytotoxic to Daudi target cells, expressed more LFA-1, and were more likely to be positive for CD2, compared to those LAK cells not adherent to the HUVEC monolayer. In contrast, in the absence of the HUVEC monolayer, there was no difference in LAK activity between migratory and non-adherent LAK cells. These results indicate that the interaction between LAK cells and the HUVEC monolayer allows selective migration of LAK cells with cytotoxic activity that is enhanced with respect to some surface molecules.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. ) Rosenberg , S. A. , Lotze , M. T. and Muul , L. M.Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin‐2 to patients with metastatic cancer . N. Engl. J. Med. , 313 , 1485 – 1492 ( 1985. ). - PubMed
    1. ) Shu , S. , Chou , T. and Rosenberg , S. A.In vitro sensitization and expansion with viable tumor cells and interleukin‐2 in the generation of specific therapeutic effector cells . J. Immunol. , 136 , 3891 – 3898 ( 1986. ). - PubMed
    1. ) Ariga , A. , Yamauchi , K. , Takasaki , K. , Furukawa , T. and Hanyu , F.Induction of autologous tumor‐specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization . Int. J. Cancer , 49 , 19 – 24 ( 1991. ). - PubMed
    1. ) Topalian , S. A. , Solomon , D. , Avis , F. P. , Chang , A. E. , Freerksen , D. C. , Linehan , W. M. , Lotze , M. T. , Lobertson , C. N. , Seipp , C. A. , Simon , P. , Simpson , C. G. and Rosenberg , S. A.Immunotherapy of patients with advanced cancer using tumor‐infiltrating lymphocytes and recombinant interleukin‐2: a pilot study . J. Clin. Oncol. , 6 , 839 – 853 ( 1988. ). - PubMed
    1. ) Pockaj , B. A. , Sherry , R. M. , Wei , J. P. , Yannelli , J. R. , Carter , C. S. , Leitman , S. F. , Carasquillo , J. A. , Steinberg , S. M. , Rosenberg , S. A. and Yang , J. C.Localization of 111Indium‐labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy . Cancer , 73 , 1731 – 1737 ( 1993. ). - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources